UsiRNA reduces tumor growth in vivo

UsiRNA reduces tumor growth in vivo

MDRNA, Inc. (NASDAQ: MRNA) presented new in vivo data showing continued progress in the advancement of the Company’s oncology program. J. Michael French, President and CEO, reported that MDRNA’s UsiRNAs, delivered by the Company’s DiLA2 platform, down-regulated a previously “non-druggable” target with subsequent reductions in tumor growth in models of liver and bladder cancer via both systemic and local delivery.

 Read the release.